Paclitaxel is a core active pharmaceutical ingredient (API) used as a first‑line clinical treatment for various solid tumors worldwide, including lung cancer, breast cancer, and others. Longzang Biotech has achieved large‑scale production of paclitaxel using yew (Taxus) stem cell suspension culture technology in 500L bioreactors, completely eliminating dependence on protected natural yew plants. This breakthrough addresses critical industry challenges such as resource scarcity, high costs, and unstable supply.

The product offers purity ≥98%, reduces production costs by over 80% compared to traditional extraction methods, and delivers high batch‑to‑batch consistency. It fully meets the requirements of pharmaceutical companies for formulation registration and large‑scale production.

-

紫杉醇是全球临床一线抗肿瘤核心原料药，广泛应用于肺癌、乳腺癌等多种实体瘤治疗。龙藏生物依托红豆杉干细胞悬浮培养技术，实现 500L 生物反应器规模化量产，彻底摆脱对天然红豆杉保护植物的依赖，解决资源稀缺、成本高昂、供应不稳定的行业痛点。产品纯度≥98%，成本较传统提取方式降低 80% 以上，批次一致性高，可满足药企制剂申报与规模化生产需求。